Femasys Inc Total Liabilities
Femasys Inc total liabilities. Based on the latest financial reports, Femasys Inc (FEMY) has total liabilities worth $8.26 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check FEMY cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Femasys Inc (2019–2025)
Total liabilities of Femasys Inc from 2019 to 2025. This chart illustrates how Femasys Inc's total liabilities have evolved over time, based on quarterly financial data.
Femasys Inc Competitors by Total Liabilities
The table below lists competitors of Femasys Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hays plc
LSE:HAS
|
UK | GBX1.30 Billion |
|
Indbank Merchant Banking Services Limited
NSE:INDBANK
|
India | Rs243.98 Million |
|
Baillie Gifford US Growth Trust PLC
LSE:USA
|
UK | GBX39.47 Million |
|
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
|
USA | $12.38 Million |
|
Sapura Resources Bhd
KLSE:4596
|
Malaysia | RM569.07 Million |
|
SAN-EL Muhendislik Elektrik Taahhut Sanayi ve Ticaret AS
IS:SANEL
|
Turkey | TL240.03 Million |
|
Ssif Broker Cl
RO:BRK
|
Romania | RON152.17 Million |
|
Salutica Bhd
KLSE:0183
|
Malaysia | RM16.82 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Femasys Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see FEMY total asset value.
Liquidity & Leverage Metrics
Femasys Inc Total Liabilities Ratios Explained
Femasys Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.67 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Femasys Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Femasys Inc (2019–2025)
The table below shows the annual total liabilities of Femasys Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $14.85 Million | +46.49% |
| 2024-12-31 | $10.14 Million | +7.84% |
| 2023-12-31 | $9.40 Million | +468.84% |
| 2022-12-31 | $1.65 Million | -26.34% |
| 2021-12-31 | $2.24 Million | -44.97% |
| 2020-12-31 | $4.08 Million | -92.97% |
| 2019-12-31 | $58.02 Million | -- |
About Femasys Inc
Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal pat… Read more